GANITE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GANITE (GANITE).
Ganite (gallium nitrate) inhibits bone resorption by reducing the activity of osteoclasts. It binds to hydroxyapatite crystals in bone, inhibiting their dissolution and preventing calcium release. It also suppresses parathyroid hormone (PTH) secretion and may inhibit prostaglandin synthesis.
| Metabolism | Gallium nitrate is not metabolized and is excreted unchanged primarily by the kidneys. Approximately 65% of a dose is excreted in urine within 24 hours. |
| Excretion | Renal: ~50% unchanged; biliary/fecal: ~50% as metabolites |
| Half-life | Terminal half-life: 30–60 minutes (clinical context: supports continuous IV infusion for sustained effect) |
| Protein binding | ~50% bound to plasma proteins (albumin) |
| Volume of Distribution | 0.08–0.15 L/kg (confined primarily to intravascular space, minimal tissue penetration) |
| Bioavailability | Oral: <5% (not administered orally) |
| Onset of Action | IV: 5–10 minutes |
| Duration of Action | 60–90 minutes (tumor cell kill limited to S-phase; prolonged exposure enhances efficacy) |
1.8 mg/m2 intravenously over 2 hours on Days 1, 8, and 15 of a 28-day cycle.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl 40-60 mL/min: 1.5 mg/m2; CrCl 20-39 mL/min: 1.2 mg/m2; CrCl <20 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce to 1.5 mg/m2; Child-Pugh C: not recommended. |
| Pediatric use | Not established; safety and efficacy in pediatric patients have not been studied. |
| Geriatric use | No specific adjustment; monitor renal function due to age-related decline in CrCl. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GANITE (GANITE).
| Breastfeeding | No human data on excretion in breast milk; gallium nitrate has high molecular weight and is protein bound, suggesting limited transfer. M/P ratio not established. Caution advised; avoid breastfeeding during therapy due to potential for renal toxicity and bone effects in infant. |
| Teratogenic Risk | Ganite (gallium nitrate) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects, including skeletal abnormalities in rats and rabbits at doses similar to human exposure. First trimester exposure carries highest risk of developmental toxicity; second and third trimester use is associated with potential fetal nephrotoxicity and altered bone metabolism. Benefit must clearly outweigh risk. |
■ FDA Black Box Warning
Ganite should not be used in patients with severe renal impairment (serum creatinine >2.5 mg/dL) because it can cause nephrotoxicity. It can also cause hypocalcemia, which may be severe and symptomatic.
| Serious Effects |
["Severe renal impairment (serum creatinine >2.5 mg/dL)","Concurrent use with other nephrotoxic drugs (e.g., aminoglycosides, amphotericin B) due to increased risk of renal failure"]
| Precautions | ["Renal toxicity: Monitor renal function closely; dose reduction or discontinuation may be necessary.","Hypocalcemia: Can cause dangerously low calcium levels; monitor serum calcium frequently.","Electrolyte disturbances: Monitor magnesium and phosphate levels.","Pregnancy: Category C; may cause fetal harm.","Nursing mothers: Discontinue nursing or drug.","Pediatric use: Safety and efficacy not established."] |
Loading safety data…
| Fetal Monitoring | Monitor renal function (serum creatinine, BUN, urinalysis) and electrolytes (magnesium, calcium, phosphate) weekly. Fetal ultrasound for growth and anomaly scan; consider amniotic fluid assessment for oligohydramnios. Maternal auditory function (ototoxicity risk) baseline and periodic. |
| Fertility Effects | No specific human data; in animal studies, gallium nitrate caused testicular degeneration and impaired spermatogenesis at high doses. Ovarian suppression or menstrual irregularities may occur. Long-term fertility impact unknown. |